Quick Answer
ANAPTYSBIO, INC reported Research And Development Expense of $88.80 million for the year ending 2022.
- ANAPTYSBIO, INC showed a decrease of -9.8% in Research And Development Expense from 2021 to 2022.
- This data is from ANAPTYSBIO, INC's annual report (Form 10-K), filed with the SEC on March 1, 2023.
- XBRL data for this metric is available from 2015 to 2022 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $4.79 million | Q2 2016: $2.34 million | Q3 2016: $3.28 million | Q1 2017: $7.94 million | Q2 2017: $7.21 million | Q3 2017: $6.70 million | Q1 2018: $11.81 million | Q2 2018: $10.58 million | Q3 2018: $17.88 million | Q1 2019: $20.63 million | Q2 2019: $27.35 million | Q3 2019: $29.93 million | Q1 2020: $20.97 million | Q2 2020: $17.95 million | Q3 2020: $19.54 million | Q1 2021: $24.19 million | Q2 2021: $25.31 million | Q3 2021: $22.22 million | Q1 2022: $22.52 million | Q2 2022: $20.84 million | Q3 2022: $22.06 million | Q1 2023: $34.96 million | Q2 2023: $32.92 million | Q3 2023: $30.88 million | Q1 2024: $37.04 million | Q2 2024: $42.00 million | Q3 2024: $42.21 million | Q1 2025: $41.18 million | Q2 2025: $37.82 million | Q3 2025: $31.41 million.
- Over the full 8 years of available data (2015 to 2022), ANAPTYSBIO, INC's Research And Development Expense has grown by 413.2%.
- Historical annual values: Fiscal year 2022: $88.80 million | Fiscal year 2021: $98.50 million | Fiscal year 2020: $80.03 million | Fiscal year 2019: $99.34 million | Fiscal year 2018: $56.20 million | Fiscal year 2017: $29.44 million | Fiscal year 2016: $15.42 million | Fiscal year 2015: $17.30 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: